| Literature DB >> 30622223 |
Satya Narayan Seervi1, Geeta Singariya1, Manoj Kamal2, Kamlesh Kumari1, Ashwini Siddeshwara1, Shobha Ujwal1.
Abstract
BACKGROUND: The transversus abdominis plane (TAP) block is an effective technique to block the thoracolumbar nerves innervating the anterolateral abdominal wall. This study was conducted to evaluate the analgesic efficacy and opioid consumption with the use of perineural buprenorphine or dexamethasone in TAP blocks after unilateral inguinal hernioplasties.Entities:
Keywords: Buprenorphine; Dexamethasone; Inguinal hernioplasty; Levobupivacaine; Transversus abdominis plane block
Year: 2019 PMID: 30622223 PMCID: PMC6547228 DOI: 10.4097/kja.d.18.00182
Source DB: PubMed Journal: Korean J Anesthesiol ISSN: 2005-6419
Fig. 1.CONSORT flow diagram.
Demographic Characteristic of the Patients
| Parameters | Group L | Group LB | Group LD | P value |
|---|---|---|---|---|
| Age (yr) | 43.67 ± 14.97 | 40.93 ± 16.15 | 42.74 ± 15.16 | 0.777 |
| Weight (kg) | 70.51 ± 4.21 | 68.80 ± 3.84 | 69.90 ± 4.80 | 0.275 |
| ASA-PS (I/II) | 15/16 | 16/15 | 16/15 | 0.799 |
| Sex (M/F) | 31/0 | 31/0 | 31/0 | N/A |
Values are presented as mean ± SD or number of patients. Group L: 20 ml 0.25% levobupivacaine group + 1 ml NS, Group LB: 20 ml 0.25% levobupivacaine + 0.3 mg (1 ml) buprenorphine, Group LD: 20 ml 0.25% levobupivacaine + 4 mg (1 ml) dexamethasone. ASA-PS: American Society of Anesthesiologists physical status, N/A: not applicable.
Fig. 2.Kaplan Meier curve of duration of analgesia.
Time Taken for the First Analgesia Request and the Total Tramadol Consumption
| Parameters | Group L | Group LB | Group LD | P value | ||
|---|---|---|---|---|---|---|
| L vs. LB | L vs. LD | LB vs. LD | ||||
| Duration of analgesia (min) | 370.0 (357.5, 417.5) | 685.0 (662.5, 707.5) | 590.0 (572.5, 632.5) | < 0.001 | < 0.001 | < 0.001 |
| 383.0 ± 36.2 | 688.8 ± 36.1 | 601.4 ± 39.8 | ||||
| Total tramadol consumption in first 24 h (mg) | 300.0 (200–300) | 200.0 (100–200) | 200.0 (100–300) | < 0.001 | < 0.001 | > 0.050 |
| 274.1 ± 44.4 | 158.1 ± 50.1 | 177.4 ± 71.6 | ||||
Values are presented as Median (interquartile Q1, Q3), Median (range) or mean ± SD. Group L: 20 ml 0.25% levobupivacaine group + 1 ml NS, Group LB: 20 ml 0.25% levobupivacaine + 0.3 mg (1 ml) buprenorphine, Group LD: 20 ml 0.25% levobupivacaine + 4 mg (1 ml) dexamethasone.
Fig. 3.(A) Comparison of mean numerical rating scale (NRS) score at rest, (B) Comparison of mean NRS score at movement.
Incidence of Side Effects
| Side effect | Group L (n = 31) | Group LB (n = 31) | Group LD (n = 31) | |||
|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |
| Nausea | 5 | 16 | 4 | 13 | 2 | 6 |
| Vomiting | 2 | 6 | 1 | 3 | 0 | 0 |
| Sedation | 2 | 6 | 1 | 3 | 0 | 0 |
| Headache | 2 | 6 | 1 | 3 | 1 | 3 |
| Dry mouth | 0 | 0 | 2 | 6 | 0 | 0 |
Values are presented as number of patients or percentage (%). Group L: 20 ml 0.25% levobupivacaine group + 1 ml NS, Group LB: 20 ml 0.25% levobupivacaine + 0.3 mg (1 ml) buprenorphine, Group LD: 20 ml 0.25% levobupivacaine + 4 mg (1 ml) dexamethasone.